Compare Pfizer with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs ASTRAZENECA PHARMA - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER ASTRAZENECA PHARMA PFIZER/
ASTRAZENECA PHARMA
 
P/E (TTM) x 48.8 126.0 38.7% View Chart
P/BV x 8.1 38.6 21.0% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 PFIZER   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-19
ASTRAZENECA PHARMA
Mar-18
PFIZER/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,8401,278 300.5%   
Low Rs2,080883 235.7%   
Sales per share (Unadj.) Rs455.0228.4 199.2%  
Earnings per share (Unadj.) Rs93.810.4 904.9%  
Cash flow per share (Unadj.) Rs109.416.3 672.7%  
Dividends per share (Unadj.) Rs22.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs658.298.8 666.4%  
Shares outstanding (eoy) m45.7525.00 183.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.54.7 137.5%   
Avg P/E ratio x31.6104.2 30.3%  
P/CF ratio (eoy) x27.166.4 40.7%  
Price / Book Value ratio x4.510.9 41.1%  
Dividend payout %24.00-   
Avg Mkt Cap Rs m135,42027,008 501.4%   
No. of employees `0002.61.4 194.0%   
Total wages/salary Rs m3,2381,535 210.9%   
Avg. sales/employee Rs Th7,911.44,210.9 187.9%   
Avg. wages/employee Rs Th1,230.91,132.2 108.7%   
Avg. net profit/employee Rs Th1,630.7191.1 853.5%   
INCOME DATA
Net Sales Rs m20,8155,710 364.5%  
Other income Rs m1,674123 1,366.4%   
Total revenues Rs m22,4895,833 385.6%   
Gross profit Rs m5,712463 1,234.0%  
Depreciation Rs m714147 484.3%   
Interest Rs m730-   
Profit before tax Rs m6,599438 1,506.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,309179 1,290.4%   
Profit after tax Rs m4,291259 1,655.9%  
Gross profit margin %27.48.1 338.5%  
Effective tax rate %35.040.8 85.7%   
Net profit margin %20.64.5 454.3%  
BALANCE SHEET DATA
Current assets Rs m27,1673,209 846.5%   
Current liabilities Rs m8,9172,070 430.9%   
Net working cap to sales %87.720.0 439.3%  
Current ratio x3.01.6 196.5%  
Inventory Days Days6872 93.7%  
Debtors Days Days3035 86.2%  
Net fixed assets Rs m8,862790 1,121.3%   
Share capital Rs m45850 915.0%   
"Free" reserves Rs m29,6562,419 1,225.8%   
Net worth Rs m30,1132,469 1,219.5%   
Long term debt Rs m250-   
Total assets Rs m39,4004,605 855.5%  
Interest coverage x91.5NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.51.2 42.6%   
Return on assets %11.15.6 196.8%  
Return on equity %14.210.5 135.8%  
Return on capital %22.117.7 124.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m428300 143.0%   
Fx outflow Rs m7862,015 39.0%   
Net fx Rs m-358-1,715 20.9%   
CASH FLOW
From Operations Rs m97888 1,112.7%  
From Investments Rs m351-94 -375.2%  
From Financial Activity Rs m-1,099NA-  
Net Cashflow Rs m231-6 -4,049.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 75.0 85.2%  
Indian inst/Mut Fund % 7.5 0.3 2,500.0%  
FIIs % 4.9 15.7 31.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 9.1 260.4%  
Shareholders   85,207 12,856 662.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   ALEMBIC  SUN PHARMA  IPCA LABS  FDC  NEULAND LABS  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


May 7, 2021 (Close)

TRACK PFIZER

PFIZER - TTK HEALTHCARE COMPARISON

COMPARE PFIZER WITH

MARKET STATS